|
Monday, March 30, 2020 |
|
中国生物制药公布2019年年度业绩 |
中国领先的创新研发驱动型医药集团—中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2019年12月31日止年度(「年度」)之财务业绩。 more info >> |
|
中國生物製藥公佈2019年年度業績 |
中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公佈截至2019年12月31日止年度(「年度」)之財務業績。 more info >> |
|
Sino Biopharm Announces 2019 Annual Results |
Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX: 1177), a leading, innovative research and development driven pharmaceutical conglomerate in the PRC, has announced its financial results for the year ended 31 December 2019 ("the year"). more info >> |
|
Tuesday, January 21, 2020 |
|
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO |
Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. more info >> |
|
Tuesday, November 26, 2019 |
|
中国生物制药公布2019年第三季度业绩 |
中国领先的创新驱动型医药集团—中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)公布截至2019年9月30日止九个月(「回顾期」)之未经审核财务业绩。 more info >> |
|
中國生物製藥公佈2019年第三季度業績 |
中國領先的創新驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公佈截至2019年9月30日止九個月(「回顧期」)之未經審核財務業績。 more info >> |
|
Sino Biopharmaceutical Announces 2019 Third Quarterly Results |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2019 ("the review period"). more info >> |
|
Thursday, August 29, 2019 |
|
中国生物制药公布2019年中期业绩 |
中国领先的创新驱动型医药集团—中国生物制药有限公司(「中国生物制药」或「公司」,连同附属公司统称「集团」)(股票编号:1177)今天公布截至2019年6月30日止六个月(「回顾期」)之未经审核财务业绩。 more info >> |
|
中國生物製藥公佈2019年中期業績 |
中國領先的創新驅動型醫藥集團—中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)今天公佈截至2019年6月30日止六個月(「回顧期」)之未經審核財務業績。 more info >> |
|
Sino Biopharmaceutical Announces 2019 Interim Results |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced today its unaudited interim results for the six months ended 30 June 2019 (the "review period").
more info >> |
|
|
|